Federal Register / Vol. 89, No. 38 / Monday, February 26, 2024 / Notices 14075 

Infection Control website (https://

www.cdc.gov/infectioncontrol/ 

guidelines/isolation/appendix/index.

html). 

The updated recommendations in 

Draft Updates: Appendix A are 

informed by review and consideration 

of available literature on transmission 

principles and infection prevention and 

control practices for each virus. Draft 

recommendations were presented to the 

Healthcare Infection Control Practices 

Advisory Committee (HICPAC), whose 

feedback was incorporated into the 

finalized draft recommendations. 

HICPAC is a Federal advisory 

committee appointed to provide advice 

and guidance to HHS and CDC 

regarding the practice of infection 

control and strategies for surveillance, 

prevention, and control of healthcareassociated infections, antimicrobial 

resistance, and related topics in United 

States healthcare settings. HICPAC 

includes, but is not limited to, 

representatives with expertise in public 

health, infectious diseases, and 

infection prevention and control. 

HICPAC also includes ex officio 

members who represent regulatory and 

other Federal agencies and liaison 

representatives from professional 

societies. 

CDC is seeking comments on the Draft 

Updates: Appendix A. Please provide 

references to new evidence and 

justification to support any suggested 

revisions or additions. This Draft 

Updates: Appendix A is not a Federal 

rule or regulation. 

Noah Aleshire, 

Chief Regulatory Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2024–03784 Filed 2–23–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2024–0014] 

Draft Infection Control in Healthcare 

Personnel: Epidemiology and Control 

of Selected Infections Transmitted 

Among Healthcare Personnel and 

Patients: Cytomegalovirus and 

Parvovirus B19 Sections and Draft 

Source Control Definition 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), in the 

Department of Health and Human 

Services (HHS), announces the opening 

of a docket to obtain comment on the 

Draft Infection Control in Healthcare 

Personnel: Epidemiology and Control of 

Selected Infections Transmitted Among 

Healthcare Personnel and Patients: 

Cytomegalovirus and Parvovirus B19 

Sections (‘‘Draft Guideline: 

Cytomegalovirus and Parvovirus B19 

Sections’’), and on the accompanying 

Draft ‘‘Source Control’’ Definition 

adapted for Infection Control in 

Healthcare Personnel to be in the 

‘‘Terminology’’ Appendix. The updated 

recommendations in the Draft 

Guideline: Cytomegalovirus and 

Parvovirus B19 Sections are intended 

for use by the leaders and staff of 

Occupational Health Services (OHS), as 

further provided herein. These updated 

recommendations will help facilitate the 

provision of occupational infection 

prevention and control services to 

healthcare personnel (HCP) who have 

been exposed or infected and may be 

contagious to others in the workplace. 

DATES: Written comments must be 

received on or before April 26, 2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0014 by either of the methods listed 

below. Do not submit comments by 

email. CDC does not accept comments 

by email. 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Healthcare Infection Control 

Practices Advisory Committee (HICPAC) 

Secretariat, Division of Healthcare 

Quality Promotion, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H16–3, Atlanta, 

Georgia 30329, Attn: Docket Number 

CDC–2024–0014. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to http://regulations.gov, including any 

personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

http://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Laura Wells, Division of Healthcare 

Quality Promotion, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H16–2, Atlanta, 

Georgia 30329; Telephone: (404) 639– 

4000. 

SUPPLEMENTARY INFORMATION: 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data related to the Draft Guideline: 

Cytomegalovirus and Parvovirus B19 

Sections, and the accompanying Draft 

‘‘Source Control’’ Definition. 

Please note that comments received, 

including attachments and other 

supporting materials, are part of the 

public record and are subject to public 

disclosure. Comments will be posted on 

https://www.regulations.gov. Therefore, 

do not include any information in your 

comment or supporting materials that 

you consider confidential or 

inappropriate for public disclosure. If 

you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be on 

public display. CDC will review all 

submissions and may choose to redact, 

or withhold, submissions containing 

private or proprietary information such 

as Social Security numbers, medical 

information, inappropriate language, or 

duplicate/near duplicate examples of a 

mass-mail campaign. Do not submit 

comments by email. CDC does not 

accept comments by email. 

Background 

The Draft Guideline: Cytomegalovirus 

and Parvovirus B19 Sections, located in 

the ‘‘Supporting & Related Material’’ tab 

of the docket, updates the Guideline for 

infection control in health care 

personnel, 1998, Part E: Epidemiology 

and Control of Selected Infections 

Transmitted Among Health Care 

Personnel and Patients, and its 

corresponding recommendations in Part 

II of the 1998 Guideline: ‘‘3. 

Cytomegalovirus;’’ and ‘‘11. 

Parvovirus.’’ The accompanying Draft 

‘‘Source Control’’ Definition adapted for 

Infection Control in Healthcare 

Personnel to be in the ‘‘Terminology’’ 

Appendix (https://www.cdc.gov/ 

infectioncontrol/guidelines/healthcarepersonnel/terminology.html) is also 

located in the ‘‘Supporting & Related 

Material’’ tab of the docket. The 1998 

Guideline provided information and 

recommendations for Occupational 

Health Services (OHS) of healthcare 

facilities and systems on the prevention 

of transmission of infectious diseases 

among healthcare personnel (HCP) and 

patients and can be found at https://

stacks.cdc.gov/view/cdc/11563. 

As described in the Executive 

Summary of this guideline (https://

www.cdc.gov/infectioncontrol/ 

guidelines/healthcare-personnel/execsummary.html), in this document, 

‘‘OHS’’ is used synonymously with 

‘‘Employee Health,’’ ‘‘Employee Health 

Services,’’ ‘‘Employee Health and 

Safety,’’ ‘‘Occupational Health,’’ and 

other such programs. OHS refers to the 


khammond on DSKJM1Z7X2PROD with NOTICES
14076 Federal Register / Vol. 89, No. 38 / Monday, February 26, 2024 / Notices 

group, department, or program that 

addresses many aspects of health and 

safety in the workplace for HCP, 

including the provision of clinical 

services for work-related injuries, 

exposures, and illnesses. In healthcare 

settings, OHS addresses workplace 

hazards including communicable 

diseases; slips, trips, and falls; patienthandling injuries; chemical exposures; 

HCP burnout; and workplace violence. 

This Draft Guideline: Cytomegalovirus 

and Parvovirus B19 Sections update is 

part of a larger guideline update: 

Infection Control in Healthcare 

Personnel. Part I, Infrastructure and 

Routine Practices for Occupational 

Infection Prevention and Control 

Services (2019), and the Diphtheria, 

Group A Streptococcus, Meningococcal 

Disease, Pertussis, and Rabies sections 

of Part II, Epidemiology and Control of 

Selected Infections Transmitted Among 

Healthcare Personnel and Patients 

(2022) are complete and have been 

published on the CDC Infection Control 

Guideline website: https://

www.cdc.gov/infectioncontrol/ 

guidelines/healthcare-personnel/ 

index.html. The Draft Guideline: 

Cytomegalovirus and Parvovirus B19 

Sections, once finalized, is intended for 

use by the leaders and staff of OHS to 

guide the management of exposed or 

infected HCP who may be contagious to 

others in the workplace. The draft 

recommendations in Draft Guideline: 

Cytomegalovirus and Parvovirus B19 

Sections update the 1998 

recommendations with current guidance 

on the management of HCP exposed to 

or potentially infected with 

cytomegalovirus or parvovirus B19, 

focusing on postexposure management, 

including postexposure prophylaxis, for 

exposed HCP and work restrictions for 

exposed or infected HCP. The adapted 

Draft ‘‘Source Control’’ Definition is 

being added to the ‘‘Terminology’’ 

Appendix of the Infection Control in 

Healthcare Personnel Guideline (https:// 

www.cdc.gov/infectioncontrol/ 

guidelines/healthcare-personnel/ 

terminology.html) because the term 

‘‘Source Control’’ is used in the Draft 

Guideline: Parvovirus B19 Section, and 

may be used in subsequent sections. 

Since 2015, the Healthcare Infection 

Control Practices Advisory Committee 

(HICPAC) has worked with national 

partners, academicians, public health 

professionals, healthcare providers, and 

other partners to develop Infection 

Control in Healthcare Personnel 

(https://www.cdc.gov/infectioncontrol/ 

guidelines/healthcare-personnel/ 

index.html) as a segmental update of the 

1998 Guideline. HICPAC is a Federal 

advisory committee appointed to 

provide advice and guidance to HHS 

and CDC regarding the practice of 

infection control and strategies for 

surveillance, prevention, and control of 

healthcare-associated infections, 

antimicrobial resistance, and related 

events in United States healthcare 

settings. HICPAC includes, but is not 

limited to, representatives with 

expertise in public health, infectious 

diseases, and infection prevention and 

control. HICPAC also includes ex officio 

members who represent regulatory and 

other Federal agencies, and liaison 

representatives from professional 

societies. Draft Guideline: 

Cytomegalovirus and Parvovirus B19 

Sections, once finalized, will be the next 

sections to be posted to the Infection 

Control in Healthcare Personnel 

website. The accompanying Draft 

‘‘Source Control’’ Definition will be 

added to the Infection Control in 

Healthcare Personnel ‘‘Terminology’’ 

Appendix (https://www.cdc.gov/ 

infectioncontrol/guidelines/healthcarepersonnel/terminology.html). 

The updated draft recommendations 

in Draft Guideline: Cytomegalovirus and 

Parvovirus B19 Sections are informed by 

reviews of the 1998 Guideline; CDC 

resources (e.g., CDC infection control 

website), infection control guidance, 

and guidelines, as noted more 

specifically in the draft document; and 

new scientific evidence, when available. 

CDC is seeking comments on the Draft 

Guideline: Cytomegalovirus and 

Parvovirus B19 Sections and the 

accompanying Draft ‘‘Source Control’’ 

Definition. Please provide references to 

new evidence and justification to 

support any suggested revisions or 

additions. This Draft Guideline: 

Cytomegalovirus and Parvovirus B19 

Sections and the accompanying Draft 

‘‘Source Control’’ Definition are not 

Federal rules or regulations. 

Noah Aleshire, 

Chief Regulatory Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2024–03783 Filed 2–23–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3456–PN] 

Medicare and Medicaid Programs; 

Application From the Joint 

Commission for Continued CMSApproval of Its Ambulatory Surgical 

Center Accreditation Program 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice with comment. 

SUMMARY: This notice acknowledges the 

receipt of an application from the Joint 

Commission for continued recognition 

as a national accrediting organization 

for Ambulatory Surgical Centers that 

wish to participate in the Medicare or 

Medicaid programs. 

DATES: To be assured consideration, 

comments must be received at one of 

the addresses provided below, by March 

27, 2024. 

ADDRESSES: In commenting, refer to file 

code CMS–3456–PN. 

Comments, including mass comment 

submissions, must be submitted in one 

of the following three ways (please 

choose only one of the ways listed): 

1. Electronically. You may submit 

electronic comments on this regulation 

to http://www.regulations.gov. Follow 

the ‘‘Submit a comment’’ instructions. 

2. By regular mail. You may mail 

written comments to the following 

address ONLY: Centers for Medicare & 

Medicaid Services, Department of 

Health and Human Services, Attention: 

CMS–3456–PN, P.O. Box 8010, 

Baltimore, MD 21244–8010. 

Please allow sufficient time for mailed 

comments to be received before the 

close of the comment period. 

3. By express or overnight mail. You 

may send written comments to the 

following address ONLY: Centers for 

Medicare & Medicaid Services, 

Department of Health and Human 

Services, Attention: CMS–3456–PN, 

Mail Stop C4–26–05, 7500 Security 

Boulevard, Baltimore, MD 21244–1850. 

For information on viewing public 

comments, see the beginning of the 

SUPPLEMENTARY INFORMATION section. 

FOR FURTHER INFORMATION CONTACT: 

Caecilia Andrews, (410) 786–2190. 

Erin Imhoff, (410) 786–2337. 

SUPPLEMENTARY INFORMATION: 

Inspection of Public Comments: All 

comments received before the close of 

the comment period are available for 

viewing by the public, including any 

personally identifiable or confidential 


khammond on DSKJM1Z7X2PROD with NOTICES